Results 81 to 90 of about 8,452 (228)

Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis

Alimentary Pharmacology &Therapeutics, EarlyView.
Among 200 patients with primary sclerosing cholangitis, 38% reported moderate to severe pruritus in the past 6 months. During 6 months of follow up, pruritus severity fluctuated significantly. Pruritus severity was linked to worse colitis activity and lower quality of life.
Richard Dean, Maryam Yazdanfar, Joseph Zepeda, Isha J. Patel, Cynthia Levy, Craig Lammert, Raghav Bordia, Duru Cosar, Katherine Specht, Daniel Pratt, Stuart C. Gordon, Lisa Forman, Fawzy Barry, Michael Li, Usha Gungabissoon, Megan M. McLaughlin, Christopher L. Bowlus   +16 more
wiley   +1 more source

RWE in Europe – An Analysis

Journal of Health Policy & Outcomes Research, 2018
Background – This paper outlines findings from four roundtable discussions involving a number of stakeholders. They aimed to improve understanding of the use of real world evidence (RWE) across Europe. They focused on the development of a three-year roadmap for the increased incorporation of RWE, increasingly recognized as a valuable source of ...
openaire   +1 more source

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

British Journal of Haematology, EarlyView.
Summary Single‐arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B‐cell lymphomas but with significant toxicities and at exceptionally high costs. The objective of this study was to evaluate the real‐world health outcomes of aggressive B‐cell lymphoma patients treated with publicly funded ...
Pierre J. A. Villeneuve, Lee Mozessohn, Nibene H. Somé, Rebecca E. Mercer, Lisa Masucci, Tom Kouroukis, Chris Bredeson, Suriya Aktar, Qi Guan, Anca Prica, Christine I. Chen, Danielle Rodin, Matthew Cheung, Munaza Chaudhry, Scott Gavura, Cassandra McKay, William W. L. Wong, Kelvin K. W. Chan   +17 more
wiley   +1 more source

Real-World Evidence BRIDGE: A Tool to Connect Protocol With Code Programming [PDF]

OBJECTIVE: To enhance documentation on programming decisions in Real World Evidence (RWE) studies. MATERIALS AND METHODS: We analyzed several statistical analysis plans (SAP) within the Vaccine Monitoring Collaboration for Europe (VAC4EU) to identify ...
Weibel, Daniel, Kurkcuoglu, Zeynep, Royo, Albert Cid, Hoxhaj, Vjola, Elbers Jhj, Roel, Sturkenboom, Miriam C J, Andaur Navarro, Constanza L, Vaz, Tiago A   +7 more
core  

RWE Geschaeftsbericht 1987/88 [PDF]

, 1989
SIGLECopy held by FIZ Karlsruhe; available from UB/TIB Hannover / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische ...
Rheinisch-Westfaelisches Elektrizitaetswerk A.G. (RWE), Essen (Germany)
core  

The place of real-world evidence in conducting clinical and economic analysis

Реальная клиническая практика: данные и доказательства
Relevance. Real-world evidence (RWE) can be widely used in cost-effectiveness analysis (CEA) and budget impact analysis (BIA) conducted to justify the inclusion of new medicines in restrictive drug lists. However, researches of RWE use experience in drug
F. V. Gorkavenko, V. V. Omelyanovskiy, S. I. Zinadinov, A. A. Kozak, D. V. Sitnikova   +4 more
doaj   +1 more source

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10

Journal of Comparative Effectiveness Research, 2022
In this latest update we discuss the transportability of comparative effectiveness evidence across countries. We highlight results of a survey indicating that European HTA agencies are reluctant to accept real-world data from other countries, review ...
Alex Simpson, Sreeram V Ramagopalan
doaj   +1 more source

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

British Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco, Patrick Harrington, Elena Torre, Hillary Catellani, Novella Pugliese, Matteo Pacilli, Annalisa Santisi, Arianna Sbriglione, Giuseppe A. Palumbo   +8 more
wiley   +1 more source

Upregulation and role of Ifng in RWE-induced allergic inflammation. [PDF]

, 2013
(A) Sensitized Balb/c mice were challenged with either PBS (◊) or RWE (▪). Quantitative PCR was done on lung RNA four hours after challenge. (B) Sensitized WT or Ifng KO mice were challenged with either PBS or RWE.
Bruce Luxon (368507), Istvan Boldogh (16539), Swapnil Vaidya (333538), Nilesh Dharajiya (333536), Sanjiv Sur (333547), Mala Sinha (248787)   +5 more
core   +1 more source

PNS219 RWE ALGORITHMS - THE BUILDING BLOCKS OF RWE QUALITY [PDF]

Value in Health, 2020
J. Murray, J. Beyrer, H. Abedtash, K. Hornbuckle   +3 more
openaire   +1 more source